What's happening
This bill prohibits step therapy protocols for medically necessary prescription drugs in specified therapeutic classes, including non-formulary drugs.
Why it matters
Limits insurer control over drug access for serious conditions. By prohibiting step therapy (or "fail first" protocols) for key therapeutic classes like oncology, neurology, rheumatology, and others, the bill prevents insurers from requiring patients to try and fail less expensive drugs before covering prescribed options, which can be critical for complex or rapidly progressing illnesses.
Improves patient and provider autonomy. Physicians and patients would have more freedom to choose the most appropriate and timely medication—potentially preventing delays or ineffective treatment that may occur under step therapy requirements.
Expands protection to non-formulary drugs. The inclusion of non-formulary drugs (those not typically covered by the insurer’s preferred drug list) ensures that even medications outside standard insurance formularies are protected from step therapy, which could benefit patients with rare or treatment-resistant conditions.
May impact insurance costs and access. While the bill prioritizes clinical judgment and patient needs, it could lead to higher prescription drug spending for insurers, which may influence premiums, cost-sharing, or drug formulary design in the broader insurance market.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
End Step Therapy for Medicines
Plain English, a few words. Used as the page title.
Sponsors
Assembly Member · Assembly District 108
History
- Referred to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Protect Access to Needed Drugs
In Senate Committee · Insurance · Sponsor Neil D. Breslin
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
582
2023-2024 Regular Sessions
IN ASSEMBLY
January 9, 2023
Introduced by M. of A. McDONALD, STECK -- read once and referred to the Committee on Insurance
AN ACT to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding a new paragraph 14 to read as follows:
(14) When establishing a step therapy protocol, a utilization review agent shall ensure that such protocol shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
§ 2. Section 4902 of the public health law is amended by adding a new subdivision 5 to read as follows:
5. When establishing a step therapy protocol, a utilization review agent shall ensure that such protocol shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
§ 3. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02499-01-3
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.